9.1.13 CLINICAL RESEARCH SHARED SERVICE The mission of the Clinical Research Shared Service (CRSS) is to integrate and facilitate the management. Coordination and conduct of clinical research at the Arizona Cancer Center (AZCC) and to ensure that the clinical trial processes meets local, state, and federal policies and regulations. The following objecfives are designed to accomplish this mission: (1) Provide centralized administrafion and processing of clinical trial documentafion via the AZCC Clinical Administration Trials Office;(2) Provide centralized Data Management and Research Nursing services with a focus on Therapeufic trials;(3) Provide pharmacy admixture and inventory maintenance for invesfigafional agents used in peer-review clinical trials in the mulfidisciplinary clinics;(4) Aid in the development of novel formulafions or combinafions of agents for invesfigators performing pilot clinical trials;(5) Oversee and ensure quality control in the conduct of AZCC clinical trials;(6) Implement a web-based clinical trials management system (Oncore?) to facilitate peer-reviewed clinical research inifiatives and reporting. Dr. Livingston is the current Director. Ms Ma, the Associate Director of Clinical Trials, assists with day-to-day operafions of the CRSS. All clinical research-related documents flow through the AZCC Clinical Trials Office (CTO) for review, processing for further distribufion and submission, and/or maintenance in study-specific regulatory files. The CTO also coordinates and provides administrafive support for the AZCC Scienfific Review Committee (SRC, Protocol Review and Monitoring System). Clinical research activities are accomplished via disease-specific teams consisfing of clinical investigators, research nurse, clinical research coordinators/data managers along with regulatory assistants (IRB Coordinators) and other administrafive support. The AZCC Data Safety and Monitoring Board (DSMB), chaired by Dr. Dragovich, is responsible for quality assurance/quality control in AZCC clinical trials. AZCC has implemented Oncore? to manage daily clinical research operafions. Usage of the CRSS is mainly by AZCC members (77%) and spans most departments and programs. 61% of AZCC member users are with peer reviewed funding. In the period of July 2007-June 2008, The total accrual of therapeufic trials in the four NCI-defined categories is 284.

Public Health Relevance

To integrate and facilitate the coordinafion and conduct of clinical research (therapeutic, prevenfion, populafion science, and translafional) at the Arizona Cancer Center (AZCC) and to ensure that the clinical trial process meets local, state, and federal policies and regulafions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-32
Application #
8077349
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
32
Fiscal Year
2010
Total Cost
$422,650
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Song, Jin H; Singh, Neha; Luevano, Libia A et al. (2018) Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther 17:2710-2721
Rice, Photini F S; Ehrichs, Kevin G; Jones, Mykella S et al. (2018) Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention? Cancer Prev Res (Phila) 11:16-26
Padilla-Rodriguez, Marco; Parker, Sara S; Adams, Deanna G et al. (2018) The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. Nat Commun 9:2980
Hupple, Clinton W; Morscher, Stefan; Burton, Neal C et al. (2018) A light-fluence-independent method for the quantitative analysis of dynamic contrast-enhanced multispectral optoacoustic tomography (DCE MSOT). Photoacoustics 10:54-64
Casillas, Andrea L; Toth, Rachel K; Sainz, Alva G et al. (2018) Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res 24:169-180
Nair, Uma S; Bell, Melanie L; Yuan, Nicole P et al. (2018) Associations Between Comorbid Health Conditions and Quit Outcomes Among Smokers Enrolled in a State Quitline, Arizona, 2011-2016. Public Health Rep 133:200-206
Smithey, Megan J; Venturi, Vanessa; Davenport, Miles P et al. (2018) Lifelong CMV infection improves immune defense in old mice by broadening the mobilized TCR repertoire against third-party infection. Proc Natl Acad Sci U S A 115:E6817-E6825
Maisel, Sabrina; Broka, Derrick; Schroeder, Joyce (2018) Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration. Oncotarget 9:6463-6477
Daenthanasanmak, Anusara; Wu, Yongxia; Iamsawat, Supinya et al. (2018) PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest 128:2787-2801
Augustus, Gaius J; Ellis, Nathan A (2018) Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms. Am J Pathol 188:291-303

Showing the most recent 10 out of 1336 publications